There have been numerous attempts to analyze and categorize the issues that underpin the development of various health disorders. Histology and integumentary have recently proven to be instrumental in determining the initial causes of some of the most severe and widespread diseases nationwide. The advances in technologies that help examine the structure and the functioning of various cells and tissues can significantly enhance the overall body of knowledge concerning some disorders. Alzheimer’s disease, which continues to undermine the quality of life of millions of older adults in the US, should be analyzed on a micro-level in a due manner, which can significantly accelerate the development of an efficient treatment strategy.
The disease is considered to be one of the most common causes of the development of dementia. Currently, there is no treatment that can cure the disorder; the available options can solely temporarily improve symptoms. The main symptoms include problems with memory and speech. Organizing thoughts, in general, becomes a complex undertaking and diminishes the quality of communication. With the increasing average life span in the country and the changing demographic, Alzheimer’s disease has become a widespread phenomenon, which has even been referred to as a full-scale epidemic in the US. Currently, millions of Americans 65 or older suffer from its symptoms.
The normal anatomy of the nervous system is underpinned by the structure of nerve tissue. The tissue consists of two types of cells: neurons and the cells that support them. Neurons represent structural electrically excitable units of the system that receive, transmit, and process electrical signals across various body parts. They are able to perform them due to the complex chemical reactions in their cells. The examination of the nerve tissue is required for the realization of the complex changes that take place in cells. Nevertheless, such observation can be performed only after death, which significantly decreases the chances of discovering an efficient treatment method in a due manner.
The original causes of Alzheimer’s disease have not yet been examined in detail. At the same time, it has become clear that the loss of neuronal connection triggers multiple harmful processes in the human brain. Mathys et al. (2019) pinpoint that disease-associated changes occurring in pathological progression are cell-type specific. At the same time, Panza et al. (2019) pinpoint that there is currently a lack of antibacterial therapy tests for Alzheimer’s disease. The disease cannot always be easily identified due to the nature of its symptoms. Moreover, family members do not always realize that specific new issues may exacerbate the changes in cognitive abilities caused by normal aging. Therefore, it is essential to introduce a sophisticated universal framework for diagnosing Alzheimer’s disease.
Therefore, it has proven to be essential to examine the patient showing any possible symptoms using various tools. Habib et al. (2020) state that RNA sequencing helps determine disease-associated astrocytes in the disease. Medical imaging, blood tests, and cognitive testing can point to the rapid development of the disease, which can allow for the introduction of various treatment options at an early stage. Dubois et al. (2021) emphasize the role of biomarkers in the development of sophisticated tools for diagnosing Alzheimer’s disease. Moreover, Schneider (2020) underlines that specific antibodies, such as aducanumab, can be successfully applied in the development of an efficient treatment method. The best strategies for preventing the development of the disease currently include high-quality nutrition, social engagement, and reasonable volumes of physical activities.
References
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S.,… & Feldman, H. H. (2021). Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. The Lancet Neurology, 20(6), 484-496.
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019). Time to test antibacterial therapy in Alzheimer’s disease. Brain, 142(10), 2905-2929.
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z.,… & Tsai, L. H. (2019). Single-cell transcriptomic analysis of Alzheimer’s disease. Nature, 570(7761), 332-337.
Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R.,… & Schwartz, M. (2020). Disease-associated astrocytes in Alzheimer’s disease and aging. Nature Neuroscience, 23(6), 701-706.
Schneider, L. (2020). A resurrection of aducanumab for Alzheimer’s disease. The Lancet Neurology, 19(2), 111-112.